Eleison Pharmaceuticals Announces Initiation of Phase 3 Trial of Glufosfamide for Second-line Treatment of Pancreatic Cancer
Published: Oct 08, 2013
ST. PETERSBURG Fla., Oct. 7, 2013 (GLOBE NEWSWIRE) -- Eleison Pharmaceuticals LLC, a specialty pharmaceutical company developing life-saving therapeutics for rare cancers, announced it has initiated a Phase III study of Glufosfamide for the second-line treatment of patients with pancreatic cancer.
Help employers find you! Check out all the jobs and post your resume.